IQ
IQV.US IQVIA Holdings Inc
- Market cap
- USD 43.7B
- P/E
- 32.3x
- P/B
- 6.56x
- ROE
- 17.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IQV.US undervalued?
Graham numberThe Graham number of IQVIA Holdings Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IQVIA Holdings Inc fundamental analysis
No fundamental analysis for IQVIA Holdings Inc yet.
IQVIA Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IQVIA Holdings Inc
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services;…
Full company profileIQVIA Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IQVIA Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.82B | 9.70B | 10.4B | 11.1B | 11.4B | 13.9B | 14.4B | 15.0B | 15.4B | 16.3B | 17.3B |
| Gross Profit | 2.07B | 3.40B | 3.67B | 3.79B | 3.86B | 4.64B | 5.03B | 5.24B | 5.38B | 5.43B | 5.72B |
| Operating Income | 642M | 719M | 741M | 777M | 731M | 1.39B | 1.80B | 1.98B | 2.20B | 2.18B | 2.12B |
| EBITDA | 849M | 1.65B | 1.88B | 2.00B | 2.08B | 2.77B | 2.91B | 3.26B | 3.45B | 2.94B | 3.40B |
| Net Income | 115M | 1.31B | 259M | 191M | 279M | 966M | 1.09B | 1.36B | 1.37B | 1.36B | 1.17B |
| EPS | 0.76 | 5.88 | 1.24 | 0.96 | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 | 7.84 | 7.03 |
| Balance Sheet | |||||||||||
| Total Assets | 21.2B | 22.7B | 22.5B | 23.3B | 24.6B | 24.7B | 25.3B | 26.7B | 26.9B | 29.9B | 30.5B |
| Total Liabilities | 12.3B | 14.4B | 15.6B | 17.0B | 18.3B | 18.6B | 19.6B | 20.6B | 20.8B | 23.3B | 23.7B |
| Shareholders' Equity | 8.63B | 8.11B | 6.71B | 6.00B | 6.00B | 6.04B | 5.77B | 6.11B | 6.07B | 6.50B | 6.66B |
| Cash & Short-term Investments | 1.24B | 1.01B | 938M | 899M | 1.90B | 1.48B | 1.31B | 1.50B | 1.84B | 2.14B | 2.42B |
| Total Debt | 7.20B | 10.2B | 11.0B | 12.0B | 12.9B | 12.4B | 13.0B | 13.9B | 14.2B | 16.2B | 16.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 860M | 970M | 1.25B | 1.42B | 1.96B | 2.94B | 2.26B | 2.15B | 2.72B | 2.65B | 2.67B |
| Capital Expenditure | 164M | 369M | 459M | 582M | 616M | 640M | 674M | 649M | 602M | 603M | 644M |
| Free Cash Flow | 696M | 601M | 795M | 835M | 1.34B | 2.30B | 1.59B | 1.50B | 2.11B | 2.05B | 2.02B |
| Ratios | |||||||||||
| ROE | 1.3% | 16.1% | 3.9% | 3.2% | 4.6% | 16.0% | 18.9% | 22.2% | 22.6% | 20.9% | 17.6% |
| ROA | 0.5% | 5.8% | 1.1% | 0.8% | 1.1% | 3.9% | 4.3% | 5.1% | 5.1% | 4.5% | 3.9% |
| Net Profit Margin | 1.7% | 13.5% | 2.5% | 1.7% | 2.5% | 7.0% | 7.6% | 9.1% | 8.9% | 8.3% | 6.8% |
| Debt to Equity | 0.83x | 1.26x | 1.64x | 2.01x | 2.15x | 2.06x | 2.26x | 2.27x | 2.33x | 2.49x | 2.45x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IQVIA Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 59.0M | 0.30 | 6.1% |
| 2020 | USD 44.0M | 0.23 | 15.8% |
| 2019 | USD 11.0M | 0.06 | 5.8% |
| 2018 | USD 4.08B | 20 | 1,573.7% |
| 2017 | USD 7.16B | 32 | 547.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns IQVIA Holdings Inc
- Insiders 1.27%
- Institutions 98.73%
- Public & others 0.00%
- Shares outstanding 165M
- Free float 156M
Top funds holding IQV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.23M | 3.17% | -1.50% | Sep 2026 |
| Vanguard 500 Index Investor | 4.32M | 2.62% | -2.47% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 3.52M | 2.14% | -2.37% | Sep 2026 |
| Oakmark Investor | 2.33M | 1.42% | -9.04% | Sep 2026 |
| iShares Core S&P 500 ETF | 2.19M | 1.33% | +0.17% | Oct 2026 |
| Oakmark Select Investor | 2.14M | 1.30% | -17.69% | Sep 2026 |
| Fidelity 500 Index | 2.14M | 1.30% | -1.26% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 2.00M | 1.21% | -0.25% | Oct 2026 |
| Vanguard Windsor II Inv | 1.73M | 1.05% | -1.84% | Sep 2026 |
| Vanguard MStar Value Index Investor | 1.57M | 0.95% | -1.67% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 1.20M | 0.73% | +0.87% | Oct 2026 |
| JHancock Disciplined Value I | 1.04M | 0.63% | 0.00% | Sep 2026 |
| Vanguard MStar Mid Cap Value ETF | 1.03M | 0.62% | -4.89% | Sep 2026 |
| Vanguard Institutional Index I | 871K | 0.53% | -2.45% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 768K | 0.47% | +0.17% | Oct 2026 |
| Artisan Global Value I USD Acc | 761K | 0.46% | -3.96% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 693K | 0.42% | -0.06% | Oct 2026 |
| JPMorgan Mid Cap Value L | 689K | 0.42% | -23.51% | Sep 2026 |
| Fidelity Mid Cap Index | 623K | 0.38% | -1.58% | Sep 2026 |
| JHancock Disciplined Value Mid Cap I | 605K | 0.37% | 0.00% | Sep 2026 |
Top institutions holding IQV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 14.5M | 8.83% | -3.18% | Jun 2026 |
| Harris Associates L.P. | 12.2M | 7.39% | +0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 10.9M | 6.62% | -1.11% | Jun 2026 |
| State Street Corp | 7.51M | 4.56% | +0.42% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 7.50M | 4.55% | -0.98% | Jun 2026 |
| JPMorgan Chase & Co | 6.14M | 3.73% | +13.54% | Jun 2026 |
| Artisan Partners Limited Partnership | 4.74M | 2.88% | -6.24% | Jun 2026 |
| Boston Partners Global Investors, Inc | 4.47M | 2.71% | +5.36% | Jun 2026 |
| Geode Capital Management, LLC | 4.45M | 2.70% | -0.20% | Jun 2026 |
| Amvescap Plc. | 3.28M | 1.99% | +0.41% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.71M | 1.64% | +3.73% | Jun 2026 |
| NORGES BANK | 2.26M | 1.37% | +2.63% | Jun 2026 |
| Franklin Templeton Inc | 2.11M | 1.28% | +317.50% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.95M | 1.18% | +65.62% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.80M | 1.10% | +4.00% | Sep 2026 |
| Northern Trust Corp | 1.71M | 1.04% | -1.20% | Jun 2026 |
| AllianceBernstein L.P. | 1.64M | 1.00% | -42.93% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 1.63M | 0.99% | +9.00% | Jun 2026 |
| AQR Capital Management LLC | 1.54M | 0.93% | +23.86% | Jun 2026 |
| Longview Partners (Guernsey) Limited | 1.50M | 0.91% | -20.91% | Jun 2026 |
IQVIA Holdings Inc company profile
- Company name
- IQVIA Holdings Inc
- Ticker
- IQV.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2013
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 95,000
- Fiscal year end
- December
- Address
- 2400 Ellis Road, Durham, NC, United States, 27703
- Phone
- 919 998 2000
- Website
- iqvia.com
About IQVIA Holdings Inc
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
IQVIA Holdings Inc management
10- Mr. Ari BousbibCEO & Chairman · born 1961
- Mr. Eric M. Sherbet J.D.Executive VP, General Counsel & Secretary · born 1964
- Mr. W. Richard Staub IIIPresident of Research & Development Solutions · born 1963
- Mr. Alistair GrenfellPresident of Commercial Solutions · born 1974
- Mr. Michael J. Fedock MBAExecutive VP & Chief Financial Officer · born 1976
- Mr. James G. BerkshireExecutive Vice President of Global Infrastructure & Operations · born 1974
- Dr. Jeffrey A. Spaeder M.D.Chief Medical & Scientific Officer
- Mr. Duane SachsSenior Vice President of Corporate Development
- Ms. Trudy SteinChief Human Resources Officer & Executive VP
- Dr. Cynthia L. Verst M.S., Pharm.D.President of Design & Delivery Innovation